Biomarker-driven treatment strategies for mCRC in the CAPRI 2-GOIM trial

Giulia Martini, MD, PhD, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy, discusses the Phase II CAPRI 2-GOIM trial (NCT05312398) of cetuximab-based treatments for metastatic colorectal cancer (mCRC) using biomarker-driven approaches. Baseline next-generation sequencing (NGS) of tumor tissue and plasma circulating tumor DNA (ctDNA) was performed to identify RAS/BRAF V600E wild type mCRC. The study found baseline plasma NGS profiling feasible and effective in reclassifying 12% of patients, revealing molecular alterations that could impact resistance to anti-EGFR drugs. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.